JERUSALEM, Nov. 3, 2021 -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that it has enrolled its first patient in the combination study of Alpha DaRT and pembrolizumab (Keytruda®) at Hadassah Medical Center in Jerusalem, Israel. The clinical trial is designed to test the benefit of the Alpha DaRT in combination with pembrolizumab, an immunotherapy drug, for the treatment of recurrent unresect